The Tapering Evidence Is Clear. What's Missing Is the Operational Answer.
A position paper from Reduce Rx. November 2026.Medicine was built for initiation, not discontinuation.
For the better part of a generation, opioid policy and opioid research have been organized around the same problem: too many patients started on long-term opioid therapy, too quickly, with too little caution. The 2016 CDC guideline addressed initiation. The aftermath revealed something that initiation-era policy had not anticipated.
When the field finally turned its attention to the patients who were already on long-term therapy — millions of them — it discovered that we did not know how to bring them back down.
The evidence is now substantial and consistent
The published record on what happens when tapering is done badly is now clear.
Agnoli and colleagues' 2021 JAMA study found a 68% increase in overdose risk and a near-doubling of mental-health crisis events among patients tapered from stable, high-dose long-term opioid therapy. Fenton's 2022 long-term follow-up showed those elevated risks persisted for at least two years after taper initiation. Hallvik's Oregon Medicaid cohort documented that abrupt discontinuation — even when it reduced prescription-opioid overdose — increased suicide risk and pushed some patients toward heroin. James and colleagues had warned of the mortality signal as early as 2019. Mark and Parish characterized how widespread rapid tapering had become across US practice from 2008 to 2017. By 2025, Yang's Medicare cohort showed that even slow tapering can be associated with increased all-cause mortality in older adults.
The regulatory response caught up. The FDA's 2019 drug safety communication required new labeling on opioid analgesics emphasizing gradual, individualized tapering and warning explicitly against abrupt discontinuation. The HHS Guide for Clinicians (2019) gave clinicians a structured eight-area framework for tapering decisions. The 2022 CDC Clinical Practice Guideline walked back the misinterpretation of the 2016 guideline and emphasized patient-centered, slow tapers. The VA/DoD's 2022 Clinical Practice Guideline went further, formally recommending buprenorphine over full-agonist opioids for long-term therapy.
The underlying evidence is settled. The guidelines have caught up. The labels have been changed.
So why does the operational gap remain so wide?
The distance between principle and prescription
The distance between taper slowly and individually as a principle and this dose, on this date, in this formulation, mapped to this refill cycle as a prescription is the gap that has not been closed.
A clinician in a 15-minute follow-up visit, looking at a stable patient on a long-standing high-dose regimen, does not lack guidance about whether a taper might be appropriate. They lack a workflow for executing the taper safely if it is. The CDC tells them what good tapering looks like in the abstract. The HHS Guide tells them what good tapering looks like as a process. Neither document tells them which available formulation to write today, on which date, with which interval, in what quantity, with what real-time signal that the chosen rate is or is not aligned with the evidence.
The existing public tools — Washington State's AMDG calculator, the CDC's MME mobile app, Oregon Pain Guidance's BRAVO! framework — are valuable. They are also incomplete. They convert doses or generate schedules without integrating dose-availability constraints, refill cycles, or real-time decision support that flags rates falling outside guideline-aligned ranges. They were never designed to.
This is the gap that, as of 2026, still produces the harms the literature has documented.
The landscape changed. The gap did not.
The pendulum has swung. Prescription-opioid prescribing has substantially declined. US drug overdose deaths have dropped sharply from the 2022 peak — opioid-involved deaths fell from approximately 83,000 in 2023 to about 55,000 in 2024, with illicit fentanyl now driving 88% of opioid mortality. The patients still on long-term prescription opioid therapy in 2026 are an increasingly selected, often older, often stable cohort — exactly the population for whom Fenton's 2022 Comparative Effectiveness study found that tapering does not reduce harms in the absence of misuse.
The mission for those of us working on this problem is no longer to reduce prescribing volume.
It is to ensure that the small number of taper and transition decisions that do happen — and there are still many, every day — happen well. That is a different mission than the one the field set itself in 2016, and it requires different tools.
What the field needs next
We lead a small healthcare technology company that has built one such tool. So the rest of this argument could fairly be read as commercial. We want to ask the question anyway, because we believe it is the right one to ask now.
The evidence base is rich enough. The guidelines are clear enough. What the field actually needs from its next generation of tapering research is not another retrospective cohort confirming what Agnoli and Fenton and Hallvik and Yang have already shown.
What it needs is pragmatic trials of the operational tools that translate that evidence into care.
The patients who get tapered safely in 2030 will be the patients whose clinicians had structured, evidence-aligned, workflow-integrated decision support in 2026. We do not yet know — because no one has formally tested it — whether tools of this kind reduce the overdose, mental-health, and mortality risks the cohort studies have so consistently documented. We should know. The evidence base demands that we close this loop.
An open invitation
We would welcome collaboration with the academic groups whose work has built this evidence. The research teams at UC Davis, the Birmingham VA, Stanford, and elsewhere have already done the hard work of documenting what is broken. The work that comes next — pragmatic, prospective, multi-center evaluation of operational answers — is co-authored by definition.
Reduce Rx exists because the literature these groups have produced demanded that someone build the operational answer. The next paper this field needs is the one that tests whether such tools deliver on that demand.
We are writing this in the open because we do not think this is a question any single company should answer alone, and we do not think it is a question the field can afford to leave un-asked.
Medicine was built for initiation, not discontinuation. The discontinuation gap survived the crisis that produced it. We have a chance, in the next five years, to close it — not with another guideline, but with the structured infrastructure that lets every guideline already on the books do the work it was written to do.
That work needs partners. We would be glad to be some of them.
Jeilymar Nazario Rodriguez is the founder of Reduce Rx. For more on the structural problem this position paper addresses, read The Discontinuation Gap. For the underlying evidence, see our maintained clinical reference.
